




Press Release

Major order for production of pharmaceutical cleanroom 3D systems

- ◆ **Laxxon Medical orders three Exentis 3D production systems**
- ◆ **Expansion of 3D tablet production in the USA and Europe**
- ◆ **Delivery to begin in current year**

Stetten, Switzerland, July 6th 2022 - EXENTIS Group AG, provider of a proprietary 3D technology platform that enables large-scale industrial manufacturing, has received a major order from Laxxon Medical Corp. for three Exentis cleanroom 3D production systems for tablet manufacturing.

As an Exentis 3D Community member, Laxxon Medical Corp. holds the exclusive worldwide licensing rights for the development, production and commercialization of pharmaceutical application forms such as tablets. Laxxon secured the licensing rights from Exentis back in 2017. Since then, Laxxon Medical Corp. and its international subsidiaries have been addressing a significant market potential and working on in-house and contract development projects with external industry partners.



Exentis 3D Cleanroom Production System

Helmut Kerschbaumer, CEO Laxxon Medical Corp. said, "Based on the Exentis 3D technology platform, we are able to mass produce 3D printed tablets for the first time together with our partners, offering remarkable benefits for our industry partners and patients."

The Exentis 3D systems on order include the new generation of industrial systems (pictured), which are modularly expandable at will.

Dr. Gereon Heinemann, CEO Exentis Group AG: "The order is further proof of our technological competence not only in industrial applications but also in the field of sophisticated clean room production. The Exentis 3D production systems, which can be expanded to a capacity of up to 500 million tablets per year, will be delivered to the U.S. and Europe."

The Exentis 3D Production Systems will be shipped over the next several quarters, beginning this year and continuing into 2023.

About Laxxon Medical

Laxxon Medical is dedicated to developing patented 3D pharmaceutical solutions that optimize products and benefit patients. The foundation of Laxxon's pharmaceutical solutions is its state-of-the-art 3D screen printing technology and the intellectual property that surrounds it. The commitment to innovation and health is driven by the expertise, integrity, agility and diversity of the Laxxon team. Laxxon offers three disruptive pathways for strategic opportunities in the pharmaceutical industry: advanced patented generics, patent extension through technology transfer, and new drug development.

About Exentis

As a solution provider, EXENTIS has a proprietary 3D technology platform that - contrary to conventional additive manufacturing technologies - allows industrial large-scale production. Industrialized Additive Manufacturing is universally applicable. For industrial or clean room applications. With free choice of materials, such as metals, ceramics, polymers, pharmaceutical or bioprinting products. 3D cold printing technology is sustainable and conserves materials as well as resources. The highly flexible 3D production technology combines rework-free component geometries with market-leading cost-benefit ratios. This allows customers to choose between producing millions of parts at Exentis or, as a member of the Exentis 3D Community, manufacturing in-house under license agreements when purchasing Exentis 3D development and production systems.

For more information, please contact:

EXENTIS Group AG

Klaus Radakovics
Chief Financial Officer
+ 41 (0) 56 520 74 06
k.radakovics@exentis-group.com

www.exentis-group.com

Laxxon Medical

Frances Hoggard
Public Relations Manager
f.hoggard@laxxon-medical.com

www.laxxonmedical.com

Visit us also on YouTube "Exentis Group"